Patent 9181345 was granted and assigned to MedImmune on November, 2015 by the United States Patent and Trademark Office.
The present invention encompasses auto-antibodies associated with autoimmune disorders. The auto-antibodies may be used, for example, in methods of treating patients, methods of diagnosing patients, methods of monitoring disease progression of patients, and methods of prognosing patients.